Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02735551 · ClinicalTrials.gov registry record · Phase 4

LARC Forward Contraceptive Counseling at MHCC

A Phase 4 study, sponsored by Oregon Health and Science University.

Terminated
Registry status
Phase 4
Development phase
3
Enrollment target

NCT02735551: Clinical Trial Phase 4 study, sponsored by Oregon Health and Science University.

NCT02735551 is a Phase 4 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02735551, a Phase 4 study, was terminated before completion, sponsored by Oregon Health and Science University.

TERMINATED
Registry status
Phase 4
Development phase
3 participants
Enrollment target

Study Summary

This prospective randomized controlled study will evaluate if Long Acting Reversible Contraceptive (LARC) forward counseling in combination with same-day LARC placement increases overall LARC uptake within a community college population compared to LARC forward counseling and referral to a secondary clinic for LARC placement. The study will be conducted at Mount Hood Community College (MHCC) in Oregon. Participants will be enrolled into three groups. All groups will receive the same standardized contraceptive counseling ("LARC forward counseling") and participants will be able to choose between a LARC method and short-acting method of birth control.

Primary Outcome

Proportion of Long Acting Reversible Contraception (LARC) uptake among women, by group assignment. This will be evaluated based on participants' self-reported ongoing use and satisfaction by group assignment on the 3-month questionnaire after the initial visit. 3 months following placement of LARC device, initiation of short acting method, and those in the control group, participants will complete a questionnaire in order to assess ongoing use and satisfaction of their contraceptive method. This

Interventions

  • DRUG Long Acting Reversible Contraception (LARC)
  • OTHER Referral for Long Acting Reversible Contraception (LARC)
  • OTHER Prescription for Short-Acting Hormonal Contraception

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2016-04
Est. Completion 2017-03-31
Phase Phase 4

Why NCT02735551 stopped before completion

NCT02735551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 3 interventions - of which Long Acting Reversible Contraception (LARC) is the first listed.

NCT02735551 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02735551 about?

NCT02735551 is a clinical study titled "LARC Forward Contraceptive Counseling at MHCC". This prospective randomized controlled study will evaluate if Long Acting Reversible Contraceptive (LARC) forward counseling in combination with same-day LARC placement increases overall LARC uptake within a community college population compared to LARC forward counseling and referral to a secondary...

What is the current status of trial NCT02735551?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2016-04. Estimated completion is 2017-03-31.

What interventions are being tested in trial NCT02735551?

The interventions under investigation include: Long Acting Reversible Contraception (LARC) (DRUG), Referral for Long Acting Reversible Contraception (LARC) (OTHER), Prescription for Short-Acting Hormonal Contraception (OTHER).

Who is sponsoring clinical trial NCT02735551?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02735551's enrollment target sits among peer trials

3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02735551, the US trial registry maintained by the National Library of Medicine. NCT02735551 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.